P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY

Autor: Veronica Gonzalez-Calle, Paula Rodríguez-Otero, Anna Sureda, Felipe de Arriba de la Fuente, Marta Reinoso Segura, Paz Ribas, Ana Pilar Gonzalez, Yolanda Gonzalez Montes, Albert Oriol, Joaquín Martinez-Lopez, Marta Sonia Gonzalez Perez, Miguel Teodoro Hernandez Garcia, Maialen Sirvent Auzmendi, Joan Blade, Juan José Lahuerta Palacios, Jesús San Miguel, Maria-Victoria Mateos

Publikováno v: HemaSphere, Vol 7, p e954902c (2023)

Externí odkaz: https://doaj.org/article/7bd60c39a32949f7b623c5b0f7c14719

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.

Autor: Belén Pérez-Pinilla, Carolina De Bonis-Braun, Minerva Montalvo Saavedra, Marta Diaz-Lopez, Paula Reyes González-Casanova, María José Rodríguez Salazar, Patricia Machado-Machado, Jose Maria Raya, Miguel Teodoro Hernandez Garcia, Sunil Lakhwani Lakhwani

Publikováno v: HemaSphere, Vol 7, p e999089d (2023)

Externí odkaz: https://doaj.org/article/941646e33d6041078bbc7624e4172dff

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Autor: Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld, Fredrik Schjesvold, Anna Nikolayeva, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Gabor Mikala, Laura Rosinol, Tatiana Konstantinova, Anargyros Symeonidis, Moshe Gatt, Arpad Illes, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hajek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernandez-Garcia, Joaquin Martinez Lopez, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Eric Voog, Mario Arnao-Herraiz, Estrella Carrillo-Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell Gorrochategui, Shang-Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Nadezhda Medvedeva, Chang-Ki Min, Roberto Mina, Katrin Palk, Ho-Jin Shin, Sang Kyun Sohn, Jason Tache, Achilles Anagnostopoulos, Jose-Maria Arguiñano, Michele Cavo, Joanne Filicko, Margaret Garnes, Janusz Halka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kim, Maria-Theresa Krauth, Irina Kryuchkova, Mihaela Cornelia Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi, Milda Rudzianskiene, Su-Peng Yeh, Maria Magdalena Alcalá-Peña, Adrian Alegre Amor, Hussain Alizadeh, Maurizio Bendandi, Gillian Brearton, Randall Brown, Jim Cavet, Najib Dally, Miklos Egyed, José Ángel Hernández-Rivas, Ain Kaare, Jean-Michel Karsenti, Janusz Kloczko, William Kreisle, Je-Jung Lee, Sigrid Machherndl-Spandl, Sudhir Manda, Ivan Moiseev, Jan Moreb, Zsolt Nagy, Santosh Nair, Albert Oriol-Rocafiguera, Michael Osswald, Paula Otero-Rodriguez, Valdas Peceliunas, Torben Plesner, Philippe Rey, Giuseppe Rossi, Don Stevens, Celia Suriu, Corrado Tarella, Anke Verlinden, Alain Zannetti

Publikováno v: The Lancet Haematology, 9(2), e98-e110. Lancet Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname

Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc03258e4b4010f40b43625027ef43b
https://doi.org/10.1016/s2352-3026(21)00381-1

P-197: A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: carinae study

Autor: Felipe de Arriba de la Fuente, Miguel Teodoro Hernandez Garcia, Juan Alfons Soler Campos, Susana Herráez Rodriguez, Mª José Moreno, Miriam Conzález Pardo, Mercedes Gironella Mesa, María Casanova Espinosa

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S143-S144

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59a27c6a0171af6574cd48e92920ebbb
https://doi.org/10.1016/s2152-2650(22)00527-4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.